Gate Neurosciences
Gate Neurosciences: Pioneering precision medicine for breakthrough CNS therapies since 2018.
Founded
2018Gate Neurosciences: Pioneering precision medicine for breakthrough CNS therapies since 2018.
Founded in 2018 and headquartered in Carmel, IN, Gate Neurosciences is a healthcare company dedicated to developing next-generation targeted therapies for central nervous system (CNS) disorders. Utilizing precision medicine approaches, the company focuses on creating breakthrough drugs for psychiatric and neurologic diseases. Their innovative pipeline includes molecules aimed at improving synaptic function, with a particular emphasis on conditions like autism spectrum disorders.
Gate Neurosciences has garnered attention for its promising research and development efforts. Notably, the company has demonstrated preclinical efficacy of its lead compound, zelquistinel, in treating autism spectrum disorders. The company actively shares its findings at major scientific meetings such as the American Society of Clinical Psychopharmacology (ASCP). Through these efforts, Gate Neurosciences is making significant strides in the field of CNS therapies, aiming to transform the treatment landscape for psychiatric and neurologic conditions.
Companies similar to Gate Neurosciences include Neurolixis, Praxis Precision Medicines, Psy Therapeutics and Alto Neuroscience.
Gate Neurosciences was founded in 2018.
Gate Neurosciences' headquarters is located in Carmel, IN, US.
Gate Neurosciences' most recent funding round was for $25M (USD) in October 2022.
As of Oct 5, 2022, Gate Neurosciences has disclosed funding of $41.1M (USD). Undisclosed round amounts are excluded.
Gate Neurosciences has 8 employees as of Feb 5, 2024.
Alto Neuroscience
